The metabolic domain has moved the furthest of any peptide class in the last five years. Incretin mimetics (GLP-1, GIP, glucagon agonists) now have the largest, cleanest human dataset of any peptide family. Paired with compounds that act through different pathways — catecholamine reuptake inhibition, HGH-fragment lipolysis — they form a well-studied compositional stack.
This protocol is designed for methodical fat loss with a preserved lean-mass profile. It is not a crash protocol. Runs 12–16 weeks.
Core compound — Retatrutide
Retatrutide (NF-008) is the triple agonist — GLP-1, GIP, and glucagon — with the strongest weight-loss signal in published Phase 2 data to date. Weekly subcutaneous dosing. Start low (1–2 mg/week) for two weeks to assess GI tolerance before titrating.
Catecholamine adjunct — Tesofensine
Tesofensine (NF-016) is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine). It acts through a fundamentally different pathway from incretin mimetics — appetite suppression plus increased basal metabolic activity. Low-dose (0.25–0.5 mg daily) is the published research range.
Lipolytic adjunct — AOD-9604
AOD-9604 (NF-021) is the HGH C-terminal fragment isolated specifically for the lipolytic signaling of growth hormone without the downstream IGF-1 effect. Less dramatic than the GLP-1 class, but clean — minimal side-effect profile, no insulin-sensitivity interaction with the core compound.
Proposed dosing window
| Compound | Frequency | Published range |
|---|---|---|
| Retatrutide |
